In MS, progression independent of relapse activity is associated with neurodegenerative processes in the spinal cord and the ...

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six ...

Researchers conducted an open-label extension study to assess the efficacy of first-line ofatumumab treatment up to 6 years in patients with relapsing multiple sclerosis.

Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of ...

“Our analysis of treatment-naïve people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years provided long-term ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients ...

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisData support frexalimab as a potential ...

The infectiousness of patients with clinical attacks of malaria depends on the presence of gametocytes in the peripheral blood. Thin smears were examined for gametocytes in a total of 401 attacks ...

A lower dose of vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with RRMS, ...

Kesimpta has been approved for the treatment of relapsing forms of multiple sclerosis in over 90 countries worldwide with more than 100,000 patients treated as of March 2024. Novartis in Neuroscience ...